Coeptis Therapeutics
COEPCoeptis Therapeutics, Inc. (NASDAQ: COEP) is a United States-based biopharmaceutical company. Its primary business focus is the development of cell therapy platforms and associated therapeutic candidates for the treatment of cancer. The company's strategy centers on advancing engineered cellular immunotherapies, which involve modifying a patient's own immune cells to target and destroy cancer cells. The company's pipeline includes several platform technologies. Its lead platform, SNAP-CAR, is designed to be a multi-antigen targeting system intended to improve the efficacy of cell therapies. Coeptis is also developing its universal, multi-donor cell therapy platform, DARIC, which aims to enable the on-demand delivery of engineered, allogeneic NK cells. These platforms are being investigated for application in hematologic malignancies and solid tumors. As a publicly traded entity, Coeptis Therapeutics operates within the competitive biotechnology and pharmaceutical sectors. The company's activities are focused on preclinical and clinical-stage research aimed at translating its cell therapy platforms into viable treatment options for cancer patients.
COEP · Stock Price
Historical price data
About
Coeptis Therapeutics, Inc. (NASDAQ: COEP) is a United States-based biopharmaceutical company. Its primary business focus is the development of cell therapy platforms and associated therapeutic candidates for the treatment of cancer. The company's strategy centers on advancing engineered cellular immunotherapies, which involve modifying a patient's own immune cells to target and destroy cancer cells. The company's pipeline includes several platform technologies. Its lead platform, SNAP-CAR, is designed to be a multi-antigen targeting system intended to improve the efficacy of cell therapies. Coeptis is also developing its universal, multi-donor cell therapy platform, DARIC, which aims to enable the on-demand delivery of engineered, allogeneic NK cells. These platforms are being investigated for application in hematologic malignancies and solid tumors. As a publicly traded entity, Coeptis Therapeutics operates within the competitive biotechnology and pharmaceutical sectors. The company's activities are focused on preclinical and clinical-stage research aimed at translating its cell therapy platforms into viable treatment options for cancer patients.